Cargando…

Liquid biopsy in cholangiocarcinoma: Current status and future perspectives

Cholangiocarcinoma (CCA) are a heterogeneous group of tumors in terms of aetiology, natural history, morphological subtypes, molecular alterations and management, but all sharing complex diagnosis, management, and poor prognosis. Several mutated genes and epigenetic changes have been detected in CCA...

Descripción completa

Detalles Bibliográficos
Autores principales: Rompianesi, Gianluca, Di Martino, Marcello, Gordon-Weeks, Alex, Montalti, Roberto, Troisi, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131901/
https://www.ncbi.nlm.nih.gov/pubmed/34040697
http://dx.doi.org/10.4251/wjgo.v13.i5.332
_version_ 1783694805931393024
author Rompianesi, Gianluca
Di Martino, Marcello
Gordon-Weeks, Alex
Montalti, Roberto
Troisi, Roberto
author_facet Rompianesi, Gianluca
Di Martino, Marcello
Gordon-Weeks, Alex
Montalti, Roberto
Troisi, Roberto
author_sort Rompianesi, Gianluca
collection PubMed
description Cholangiocarcinoma (CCA) are a heterogeneous group of tumors in terms of aetiology, natural history, morphological subtypes, molecular alterations and management, but all sharing complex diagnosis, management, and poor prognosis. Several mutated genes and epigenetic changes have been detected in CCA, with the potential to identify diagnostic and prognostic biomarkers and therapeutic targets. Accessing tumoral components and genetic material is therefore crucial for the diagnosis, management and selection of targeted therapies; but sampling tumor tissue, when possible, is often risky and difficult to be repeated at different time points. Liquid biopsy (LB) represents a way to overcome these issues and comprises a diverse group of methodologies centering around detection of tumor biomarkers from fluid samples. Compared to the traditional tissue sampling methods LB is less invasive and can be serially repeated, allowing a real-time monitoring of the tumor genetic profile or the response to therapy. In this review, we analysis the current evidence on the possible roles of LB (circulating DNA, circulating RNA, exosomes, cytokines) in the diagnosis and management of patients affected by CCA.
format Online
Article
Text
id pubmed-8131901
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-81319012021-05-25 Liquid biopsy in cholangiocarcinoma: Current status and future perspectives Rompianesi, Gianluca Di Martino, Marcello Gordon-Weeks, Alex Montalti, Roberto Troisi, Roberto World J Gastrointest Oncol Review Cholangiocarcinoma (CCA) are a heterogeneous group of tumors in terms of aetiology, natural history, morphological subtypes, molecular alterations and management, but all sharing complex diagnosis, management, and poor prognosis. Several mutated genes and epigenetic changes have been detected in CCA, with the potential to identify diagnostic and prognostic biomarkers and therapeutic targets. Accessing tumoral components and genetic material is therefore crucial for the diagnosis, management and selection of targeted therapies; but sampling tumor tissue, when possible, is often risky and difficult to be repeated at different time points. Liquid biopsy (LB) represents a way to overcome these issues and comprises a diverse group of methodologies centering around detection of tumor biomarkers from fluid samples. Compared to the traditional tissue sampling methods LB is less invasive and can be serially repeated, allowing a real-time monitoring of the tumor genetic profile or the response to therapy. In this review, we analysis the current evidence on the possible roles of LB (circulating DNA, circulating RNA, exosomes, cytokines) in the diagnosis and management of patients affected by CCA. Baishideng Publishing Group Inc 2021-05-15 2021-05-15 /pmc/articles/PMC8131901/ /pubmed/34040697 http://dx.doi.org/10.4251/wjgo.v13.i5.332 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Review
Rompianesi, Gianluca
Di Martino, Marcello
Gordon-Weeks, Alex
Montalti, Roberto
Troisi, Roberto
Liquid biopsy in cholangiocarcinoma: Current status and future perspectives
title Liquid biopsy in cholangiocarcinoma: Current status and future perspectives
title_full Liquid biopsy in cholangiocarcinoma: Current status and future perspectives
title_fullStr Liquid biopsy in cholangiocarcinoma: Current status and future perspectives
title_full_unstemmed Liquid biopsy in cholangiocarcinoma: Current status and future perspectives
title_short Liquid biopsy in cholangiocarcinoma: Current status and future perspectives
title_sort liquid biopsy in cholangiocarcinoma: current status and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131901/
https://www.ncbi.nlm.nih.gov/pubmed/34040697
http://dx.doi.org/10.4251/wjgo.v13.i5.332
work_keys_str_mv AT rompianesigianluca liquidbiopsyincholangiocarcinomacurrentstatusandfutureperspectives
AT dimartinomarcello liquidbiopsyincholangiocarcinomacurrentstatusandfutureperspectives
AT gordonweeksalex liquidbiopsyincholangiocarcinomacurrentstatusandfutureperspectives
AT montaltiroberto liquidbiopsyincholangiocarcinomacurrentstatusandfutureperspectives
AT troisiroberto liquidbiopsyincholangiocarcinomacurrentstatusandfutureperspectives